PTC Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

PTC Therapeutics CEO'su Matt Klein, Mar2023 tarihinde atandı, in görev süresi 1.67 yıldır. in toplam yıllık tazminatı $ 8.94M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.4% maaş ve 91.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.068% ine doğrudan sahiptir ve bu hisseler $ 2.12M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.7 yıl ve 9.4 yıldır.

Anahtar bilgiler

Matt Klein

İcra Kurulu Başkanı

US$8.9m

Toplam tazminat

CEO maaş yüzdesi	8.4%
CEO görev süresi	1.7yrs
CEO sahipliği	0.07%
Yönetim ortalama görev süresi	5.7yrs
Yönetim Kurulu ortalama görev süresi	9.4yrs

Son yönetim güncellemeleri

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

Oct 09

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Sep 12

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

Jun 28

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27

CEO Tazminat Analizi

Matt Klein'un ücretlendirmesi PTC Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$480m
Mar 31 2024	n/a	n/a	-US$579m
Dec 31 2023	US$9m	US$747k	-US$627m
Sep 30 2023	n/a	n/a	-US$642m
Jun 30 2023	n/a	n/a	-US$618m
Mar 31 2023	n/a	n/a	-US$571m
Dec 31 2022	US$5m	US$598k	-US$559m

Tazminat ve Piyasa: Matt 'nin toplam tazminatı ($USD 8.94M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.65M ).

Tazminat ve Kazançlar: Matt şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Matt Klein (52 yo)

1.7yrs

Görev süresi

US$8,937,025

Tazminat

Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Matthew Klein	CEO & Director	1.7yrs	US$8.94m	0.068% $ 2.1m
Stuart Peltz	Co-Founder	26.8yrs	US$5.66m	0% $ 0
Allan Jacobson	Co-Founder	26.8yrs	US$511.98k	0.016% $ 499.7k
Pierre Gravier	Chief Financial Officer	1.3yrs	US$3.01m	0.016% $ 482.8k
Mark Boulding	Executive VP & Chief Legal Officer	12.7yrs	US$2.19m	0.063% $ 2.0m
Eric Pauwels	Chief Business Officer	9.6yrs	US$2.41m	0.026% $ 798.5k
Lee Golden	Executive VP & Chief Medical Officer	4.5yrs	US$2.39m	0.019% $ 601.8k
Christine Utter	Senior VP	5.4yrs	US$1.70m	0.022% $ 690.2k
Neil Almstead	Chief Technical Operations Officer	5.9yrs	US$2.67m	0.054% $ 1.7m
Linda Carter	Senior VP & Chief Information Officer	less than a year	Veri yok	Veri yok
Alex Kane	Investor Relations Officer	no data	Veri yok	Veri yok
Jane Baj	Vice President of Corporate Communications	no data	Veri yok	Veri yok

5.7yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: PTCT 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Matthew Klein	CEO & Director	1.7yrs	US$8.94m	0.068% $ 2.1m
Stuart Peltz	Co-Founder	1.7yrs	US$5.66m	0% $ 0
Allan Jacobson	Co-Founder	26.8yrs	US$511.98k	0.016% $ 499.7k
Michael Schmertzler	Independent Chairman of the Board	23.3yrs	US$816.96k	1.95% $ 60.8m
David Southwell	Independent Director	18.9yrs	US$438.98k	0.014% $ 424.9k
Eric Jacobsen	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Emma Reeve	Independent Director	5.9yrs	US$441.98k	0.0094% $ 291.4k
Joseph Puglisi	Member of Scientific Advisory Board	21yrs	Veri yok	Veri yok
Glenn Steele	Independent Director	9.4yrs	US$426.98k	0.014% $ 424.9k
Marvin Wickens	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Schneider	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stephanie Okey	Independent Director	5.9yrs	US$421.98k	0.0076% $ 237.5k

9.4yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PTCT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.4 yıldır).

PTC Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

CEO, COO & Director recently sold US$63k worth of stock

Recent updates

PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission

PTC Therapeutics, Inc. Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Maintains Negative Opinion on Translarna Reexamination

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth

PTC Therapeutics, Inc. Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Announces Sepiapterin Nda Submission to Fda

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

New minor risk - Share price stability

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

Consensus revenue estimates increase by 11%

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

Price target decreased by 12% to US$45.64

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

Consensus EPS estimates upgraded to US$4.26 loss

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

Price target increased by 8.6% to US$57.64

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Forecast to breakeven in 2025

Co-Founder recently sold US$120k worth of stock

Chief Operating Officer notifies of intention to sell stock

Co-Founder recently sold US$86k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023

PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors

PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil

Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™

Price target decreased to US$51.46

Insufficient new directors

Price target decreased to US$52.31